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Hypothesis: EUS-FNA is useful to stage mediastinal lymph nodes in 
patients with malignant mesothelioma
Methods: A prospective two-center study investigated the diagnostic 
yield of EUS-FNA in the mediastinal lymph node staging of pleural 
mesothelioma as compared to surgical staging by cervical mediasti-
noscopy and post-resectional ﬁndings. Selected patients with pleural 
mesothelioma, were staged by spiral-CT, PET scanning, EUS-FNA and 
cervical mediastinoscopy. Patients without mediastinal lymph node 
invasion were treated with induction chemotherapy with 3 cycles of 
cisplatin and pemetrexed. In patients with a radiological respons or 
stable disease, an extrapleural pneumonectomy was performed with 
optional adjuvant radiotherapy. 
Results: Thirty-six patients were registered from June 2004 until Janu-
ary 2007. Data of 22 patients (61%) were available for this abstract. 
This involved 19 males (86%), the median age was 59 years (40-67 
years). Pathological subtypes were 1 sarcomatous, 18 epithelial and 
3 mixed mesotheliomas. EUS-FNA identiﬁed suspicious mediastinal 
lymph node in 9 patients (41%) and demonstrated malignant cells in 
3 (14%). Cervical mediastinoscopy was subsequently performed in 
17 (77%) patients. The results from the mediastinoscopy revealed no 
additional patients with malignant mediastinal lymph node invasion 
(EUS-FNA sensitivity 100%). 
Conclusion: This is the ﬁrst prospective study on the use of EUS-FNA 
in patients with malignant pleural mesothelioma. The prevalence of 
mediastinal lymph node metastasis in these selected mesothelioma 
patients is low. Although this is only a preliminary analysis, EUS-FNA 
appears to have an at least comparable yield as cervical mediastinosco-
py in identifying malignant mediastinal lymph nodes. The ﬁnal analysis 
will be presented at the conference.
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randomized phase II trial of gemcitabine/cisplatin (GC) plus 
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Background: Vascular endothelial growth factor (VEGF) plays a key 
role in mesothelioma biology. High serum VEGF is a negative prognos-
tic factor in mesothelioma patients which is inversely correlated with 
survival. Bevacizumab (Avastin™) is a recombinant humanized mono-
clonal antibody to VEGF. In phase II trials in mesothelioma patients, 
gemcitabine plus cisplatin on a 21-day schedule produces response 
rates of 16% to 26% and yields a median overall survival (OS) of 9.6 to 
13 months. We evaluated the role of adding bevacizumab to gem-
citabine plus cisplatin in a double-blind, placebo-controlled randomized 
phase II trial.
Methods: Eligible patients had unresectable, histologically-conﬁrmed 
mesothelioma; no prior chemotherapy; performance status 0-1; uni-
dimensionally measurable disease; no tumor invasion of major vessels; 
no bleeding or thrombosis. Progression-free survival (PFS) was the 
primary endpoint. Statistics: 90% power to detect a hazard ratio of 
0.57. Patients were stratiﬁed by performance status (0/1) and histology 
(epithelial/other). Gemcitabine 1250 mg/m2 days 1, 8, every 21 days, 
cisplatin 75 mg/m2 day 1 every 21 days, and bevacizumab 15 mg/kg or 
placebo day 1 every 21 days, was given for 6 cycles, then bevacizumab 
or placebo every 21 days until progression. Baseline plasma VEGF 
was measured. 115 patients enrolled from December 2001 to July 2005 
at 11 sites; 108 (GCB/GCP) 53/55 were evaluable. Male 74%/84%; 
median age 62/65 (range 44-78/20-84); performance status 1 55%/47%; 
epithelial 74%/67%, sarcomatoid/biphasic/other 26%/33%; pleural 
93%/91%, peritoneal 8%/7%, tunica vaginalis 0%/2%; thrombocytosis 
40%/40%, leukocytosis 53%/47%.
Results: Cycles administered (GCB/GCP): total 458/424, median 7/6, 
range 1-42/2-39. Median progression-free survival was 6.9/6.0 months 
(HR 0.93, p=0.88). Median overall survival was 15.6/14.7 months 
(p=0.91). 1-year survival was 59%/57%. Best response: complete 
0%/0%, partial 25%/22%, stable disease 51%/60%. Median VEGF 
(N=56) 131/154 pg/ml (range 31-1760/5-1786). Higher VEGF was 
associated with shorter progression-free (p=0.02) and overall survival 
(p=0.0066). Progression-free (p=0.043) and overall survival (p=0.028) 
were signiﬁcantly better for GCB than GCP in those patients with 
baseline VEGF levels at or below the median; in the high VEGF strata 
there were no signiﬁcant differences in PFS (p=0.24) or OS (p=0.90) 
between treatment arms. Toxicities that were statistically signiﬁcantly 
different between treatment arms (p <0.05), any grade, were: alopecia 
60%/38%; epistaxis 62%/24%; hypertension 45%/22%; non-neutrope-
nic infection 15%/4%; proteinuria 62%/47%; stomatitis 23%/7%. There 
were no statistically signiﬁcantly different toxicities grade 3 or greater. 
Conclusion: In mesothelioma patients, adding bevacizumab to gem-
citabine/cisplatin does not yield statistically signiﬁcant differences in 
progression-free survival, overall survival, response, or grade ı toxicity. 
Bevacizumab-treated patients with low VEGF levels had longer pro-
gression-free and overall survival. 
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Background. A major obstacle to successful cancer treatment is the 
resistance of cancer cells to drugs. Tumors may develop drug resis-
tance during the course of treatment (acquired drug resistance) or 
may possess the innate drug resistance that plays a major role in poor 
prognosis. Mesothelioma is an aggressive, asbestos-related cancer 
that is locally invasive and rapidly (7-10 month) fatal. Until recently, 
mesotheliomas were considered to be notoriously chemoresistant 
tumors. Pemetrexed (Alimta®) plus cisplatin regimen changed this 
perception by demonstrating an increase in the response rate up to 45% 
and survival improvement in patients with unresectable mesotheliomas. 
However, along with the drug responsive patients, there was a cohort of 
patients with no positive outcome. Understanding the mechanisms of 
tumor innate drug sensitivity in mesothelioma is crucial for the devel-
opment of effective treatment regimens that may help to overcome both 
innate and acquired resistance.
Methods. We carried out a retrospective study on a cohort of mesothe-
lioma patients who showed or failed to show a strong primary response 
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to the A&C regimen. Tumors were resected prior to drug treatment and 
their RNAs analyzed using the microarray Affymetrix platforms fol-
lowed by the unsupervised cluster analysis. Genes-discriminators were 
then validated by RT-PCR on tumor and normal tissue-matched clinical 
samples. 
Results. We found a clear segregation of drug responsive vs. drug 
resistant patients based on the analysis of differentially expressed 
genes. SLC39A8, PMCA1, and PLCB1 were identiﬁed as the most 
robust discriminators of these two groups with higher expression levels 
in the drug-sensitive cohort. SLC39A8 encodes a zinc, cadmium (and, 
possibly, platinum) inﬂux transporter that may sensitize the cell to 
cisplatin effect. PMCA1 (ATP2B1) is a member of the P-type family of 
primary ion transport ATPases involved in the maintenance of intracel-
lular calcium homeostasis, while PLCB1 is a phosphoinositide-speciﬁc 
phospholipase that uses calcium as a cofactor and plays an important 
role in the intracellular transduction of extracellular signals. The last 
two aforementioned genes are most likely involved in the apoptotic 
pathways, and may facilitate, in particular, cancer cell death upon drug 
treatment. Expression of these three genes showed a remarkable cor-
relation in tumor and matched normal samples suggesting involvement 
in the same cellular process.
Conclusions: Our data link SLC39A8, PMCA1, and PLCB1 expres-
sion with the sensitivity of mesothelioma to pemetrexed and cisplatin. 
Studies on overexpressed or silenced SLC39A8, PMCA1 and PLCB1 
are underway to further investigate their roles in the innate resistance to 
these and other drugs. The ﬁnal goal of this study is developing a tool 
to sensitize cancer cells prior to drugs administration to ensure more 
effective and speciﬁc chemotherapy. 
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Correlations of biomarker expression and clinical outcome in a 
large phase III trial of pemetrexed plus cisplatin or gemcitabine 
plus cisplatin in chemonaive patients with locally advanced or 
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Background: A recently completed phase III study demonstrated that 
pemetrexed plus cisplatin (PC) had similar efﬁcacy and better tolerability 
than gemcitabine plus cisplatin (GC) in 1725 chemonaive patients with 
advanced NSCLC. As part of this phase III trial, we quantiﬁed mRNA 
and protein levels in pretreatment biopsies to identify biomarkers that 
may predict the clinical outcome of patients treated with PC or GC.
Methods: Chemonaive patients with stage IIIB or IV NSCLC were 
randomly assigned to receive up to 6 cycles of PC (pemetrexed 500 
mg/m2 plus cisplatin 75 mg/m2 on day 1) or GC (gemcitabine 1250 
mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on day 1). Both arms 
received folic acid and vitamin B12 supplementation. More than 200 
formalin-ﬁxed parafﬁn-embedded tissue samples were available for 
gene expression and immunohistochemistry (IHC) analyses. We se-
lected markers involved in the drug pathway or with pathways targeted 
by other NSCLC treatments. These markers included thymidylate 
synthase (TS) for pemetrexed, ribonucleotide reductase M1 (RRM1) 
for gemcitabine, excision repair cross-complementing 1 (ERCC1) for 
cisplatin, and epidermal growth factor receptor (EGFR) for EGFR 
tyrosine kinase inhibitors.
Results: Of 232 patients with tissue samples, 69 had gene expres-
sion results and 181 had IHC results. Treatment-related differences in 
clinical outcomes were not consistently associated with pretreatment 
biomarker expression for the 9 genes evaluated. However, high EGFR 
expression was associated with improved clinical outcomes indepen-
dent of treatment. When patients were categorized into binary expres-
sion groups (“high” and “low” pretreatment mRNA expression), high 
EGFR was associated with improved progression-free survival (PFS) 
and time to progressive disease (TtPD) regardless of treatment (PFS 
HR = 0.344, 95% CI 0.19-0.63, p = 0.009; TtPD HR = 0.404, 95% 
CI 0.22-0.76, p = 0.049). Several analyses showed weak associations 
between TS expression and clinical outcomes. A statistically signiﬁ-
cant interaction between TS expression level and treatment effect (p 
= 0.014) was identiﬁed for TtPD. Speciﬁcally, a per-unit change in 
relative gene expression (Δ CT), equal to a doubling in TS gene copy 
number, predicted a 25% increase in hazard of tumor progression for 
PC patients and a 38% decrease in hazard for GC patients.
Conclusions: High levels of EGFR gene expression appear to predict 
better clinical outcomes in chemonaive patients with stage IIIB/IV 
NSCLC. Our results also suggest a potential association between low 
TS expression and improved outcomes with PC. Larger translational 
research studies are needed to determine the prognostic or predictive 
value of these biomarkers.
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Prospective study assessing MDM2 309 and p53 Arg72Pro single 
nucleotide polymorphism (SNPs) and clinical outcome in advanced 
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Background: After DNA damage, the p53Arg allele of the Arg72Pro 
SNP (rs1042522:C>G) has a higher pro-apoptotic activity, while the 
p53Pro allele more efﬁciently induces cell cycle arrest. The G allele of 
the MDM2 SNP309 (rs2279744:T>G) expresses higher levels of the 
protein thus attenuating the p53 pathway. Both SNPs have been shown 
to affect lung cancer risk. We aimed to investigate their relationship 
with the clinical outcome of chemotherapy.
Methods: We prospectively recruited 426 consecutive patients with 
advanced disease (352 NSCLC and 74 SCLC, 57% metastatic) referred 
